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Abstract
Background: Fibromyalgia syndrome (FMS), a common, chronic, widespread musculoskeletal pain disorder found in 2% of
the general population and with a preponderance of 85% in females, has both genetic and environmental contributions.
Patients and their parents have high plasma levels of the chemokines MCP-1 and eotaxin, providing evidence for both a
genetic and an immunological/inflammatory origin for the syndrome (Zhang et al., 2008, Exp. Biol. Med. 233: 1171–1180).
Methods and Findings: In a search for a candidate gene affecting inflammatory pathways, among five screened in our
patient samples (100 probands with FMS and their parents), we found 10 rare and one common alleles for MEFV, a gene in
which various compound heterozygous mutations lead to Familial Mediterranean Fever (FMF). A total of 2.63 megabases of
genomic sequence of the MEFV gene were scanned by direct sequencing. The collection of rare missense mutations (all
heterozygotes and tested in the aggregate) had a significant elevated frequency of transmission to affecteds (p=0.0085,
one-sided, exact binomial test). Our data provide evidence that rare missense variants of the MEFV gene are, collectively,
associated with risk of FMS and are present in a subset of 15% of FMS patients. This subset had, on average, high levels of
plasma IL-1b (p=0.019) compared to FMS patients without rare variants, unaffected family members with or without rare
variants, and unrelated controls of unknown genotype. IL-1b is a cytokine associated with the function of the MEFV gene
and thought to be responsible for its symptoms of fever and muscle aches.
Conclusions: Since misregulation of IL-1b expression has been predicted for patients with mutations in the MEFV gene, we
conclude that patients heterozygous for rare missense variants of this gene may be predisposed to FMS, possibly triggered
by environmental factors.
Citation: Feng J, Zhang Z, Li W, Shen X, Song W, et al. (2009) Missense Mutations in the MEFV Gene Are Associated with Fibromyalgia Syndrome and Correlate
with Elevated IL-1b Plasma Levels. PLoS ONE 4(12): e8480. doi:10.1371/journal.pone.0008480
Editor: Derya Unutmaz, New York University, United States of America
Received October 24, 2009; Accepted November 22, 2009; Published December 30, 2009
Copyright:  2009 Feng et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This research was supported by a grant from the Los Angeles Fibromyalgia Foundation and in part by an National Institutes of Health General Clinical
Research Center Grant, M01 RR00043. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: jshively@coh.org (JES); ssommer@medomics.com (SSS)
. These authors contributed equally to this work.
Introduction
Fibromyalgia syndrome (FMS) is characterized by chronic,
widespread pain in the muscles and joints. FMS is also
accompanied by a variety of other common symptoms, including
sleep disturbance, fatigue, headache and mood disorders [1]. The
prevalence of FMS in the general population is estimated at 2%,
where 85% of the affected are females [2]. The current American
College of Rheumatology (ACR) criteria for diagnosis/entry into a
clinical trial relies on the scoring of 11/18 positive tender points
plus widespread pain lasting for more than 3 months [3]. The
etiology of FMS is elusive, with proposals ranging from over-
sensitivity to pain to chronic infections. Both familial and genetic
studies suggest a role for genetic factors in the development of
FMS.
Family studies showed a strong familial aggregation of FMS and
related conditions [4,5,6]. A possible role of genetic and familial
factors in this syndrome was studied in 58 offspring originating
from 20 complete nuclear families ascertained through affected
mothers with FMS [7]. Indeed, a high prevalence of FMS was
observed among offspring of FMS mothers. Since psychological
and familial factors were not different in children with and without
FMS, the high familial occurrence of this syndrome may be
attributable to genetic factors [7]. In a more comprehensive family
study, Arnold et al. [5] assessed familial aggregation of FMS with
measures of tenderness and pain, and familial co-aggregation of
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odds of FMS in a relative of a proband with FMS versus the odds
of FMS in a relative of a proband with rheumatoid arthritis (RA)
was 8.5. The number of tender points was significantly higher and
the total myalgic score was significantly lower in the relatives of
FMS probands compared with relatives of RA probands. The
results of this study indicate that FMS and reduced pressure pain
thresholds aggregate in families, and that FMS co-aggregates with
major mood disorder in families. These findings have clinical and
theoretical implications, including the possibility that genetic
factors are involved in the etiology of FMS and pain sensitivity.
Studies in search of the genetic predisposition to FMS have been
conducted based on the strong evidence of a familial aggregation in
FMS. The genes involved in serotoninergic neurotransmission are
of special interest in FMS, as this neurotransmitter not only partially
mediates central pain perception, but also functions to regulate
anxiety related traits often associated with FMS [8,9,10,11,12]. The
silent T102C polymorphism of the 5-HT2A-receptor gene was
investigated in 168 FMS patients and 115 healthy controls [13,14].
A significantly different genotype distribution was shown, in which
FMS patients had fewer T/T and more frequent T/C and C/C
genotypes ascompared to thecontrolpopulation(Fisher’s exacttest,
two-sided, p=0.008). Genotypes were unrelated to age of onset,
duration of disease or psychopathological symptoms. Self-reported
information on pain severity was significantly higher in patients of
the T/T genotype, which suggested that the T102-allele might be
involved in the complex circuits of nociception. The T102C
polymorphism might be in linkage disequilibrium with the true
functional variant [13].
A second gene investigated, catechol-O-methyltransferase
(COMT), encodes an enzyme that inactivates catecholamines
and catecholamine-containing drugs. The significance of COMT
polymorphisms was assessed in 61 FMS patients and 61 healthy
controls [15]. The LL and LH genotypes together were more
highly represented in patients than controls (p=0.024), and HH
genotypes in patients were significantly lower than in the control
group (p=0.04). It was concluded that COMT polymorphisms
would be of potential pharmacological importance regarding
individual differences in the metabolism of catechol drugs and may
also be involved in the pathogenesis and treatment of FMS
through adrenergic mechanisms, as well as genetic predisposition
to FMS [15].
Though several lines of evidence suggest a role for polymor-
phisms of genes in the serotoninergic, catecholaminergic and
dopaminergic [16] systems in the etiopathogenesis of FMS, these
polymorphisms are not specific for FMS and are similarly
associated with additional co-morbid conditions. Currently, no
evidence has emerged to point to a monogenic mode of
transmission, while a multi-factorial mode of transmission is
generally presumed [17].
Recently, we have investigated the possibility that FMS has an
immunological basis [18], an idea that remains controversial
[19,20,21]. In support of this idea, biopsies of FMS skeletal
muscles showed defects that may have been caused (among other
possibilities) by an inflammatory disorder [22]. We found that both
patients and their parents had high plasma levels of the
chemokines MCP-1 (p,0.001) and eotaxin (p,0.01), supporting
both the genetic and immunological basis for this syndrome [18].
Possible immunological triggers for FMS include intestinal
inflammation such as found in irritable bowel syndrome (IBS), a
condition found in a large percentage (ca. 50%) of FMS patients
[23,24].
In a search for possible candidate genes that are associated with
conditions such as inflammation of the bowel, as well as other
organs, we became interested in the gene MEFV, in which a
number of mutations cause Familial Mediterranean Fever (FMF).
FMF is an autosomal recessive disorder characterized by recurrent
attacks of fever and inflammation in the peritoneum, synovium, or
pleura, and accompanied by pain [25,26]. Clinical features show
that FMS and FMF have some overlapping symptoms, such as
chronic lower body pain, points of tenderness, and widespread
pain.
The MEFV gene, located on chromosome 6p13.3, has 10 exons
and encodes a 781 amino acid protein, termed pyrin. Pyrin
contains the PYD domain, which belongs to a member of the six-
helix bundle, death-domain superfamily that includes death
domains, death effector domains, and caspase activation and
recruitment domains (CARDs). The NLR (nucleotide binding
domain and leucine rich, or NOD-like receptor, where NOD is an
abbreviation for nucleotide oligomerization domain) family of
genes also contain the PYD domain [27,28,29,30]. While the pyrin
protein is thought to function in apoptotic and inflammatory
signaling pathways [31,32], its exact function has been debated. In
a better-studied system, cryopyrin or NLRP3, which also has the
PYD domain, is activated to assemble the inflammasome [33], a
multi-protein structure that ultimately results in activation of pro-
caspase-1 that, in turn, processes pro-IL-1b to IL-1b. Upon release
from monocytes, IL-1b causes fever. Notably, rare mutations in
the cryopyrin gene (NLRP3 or CIAS1) are dominant, leading to a
variety of serious syndromes [34,35,36,37,38]. The current
hypothesis for the role of pyrin in FMF is that wild type pyrin
inhibits, while mutated pyrin fails to inhibit, the inflammasome
[39]. This situation would be similar to the role of NOD2 in
Crohn’s disease, in which wild type NOD2, also a member of the
NLR family [40], inhibits TLR2 (toll-like receptor-2) activation by
peptidoglycan, while mutated NOD2 fails to inhibit TLR2,
leading to chronic inflammation in the bowel [41]. More recently,
the pyrin-domain-containing protein, HIN-200, has been shown
to regulate caspase activation in response to foreign double-
stranded DNA [42], further suggesting that members of the NLR
gene family, especially the PYD-domain-containing members,
regulate inflammation.
To explore the possibility that mutations in the MEFV gene may
predispose to FMS, we sequenced the regions of likely functional
significance in the MEFV gene, exons and splice junctions, in 100
FMS probands and their parents (trios), plus a small number of
affected siblings. We hypothesized that rare missense variants
would, collectively, be found at elevated frequency in affected
individuals. This hypothesis is based on the observation that
different rare mutations in the MEFV gene (,5% population
frequency) can lead to FMF when they are compound heterozy-
gous, reports that rare mutations in the related cryopyrin gene act
as dominant risk alleles for a variety of syndromes, and published
theoretical arguments that low allele frequency can serve as a
predictor of functional significance [43]. It is possible that rare
mutations on a single haplotype in the MEFV gene cause milder
symptoms than those in the compound heterozygous state
associated with FMF or, more likely, that additional factors
present in the environment may trigger FMS.
We found 10 rare missense mutations, occurring in combina-
tions forming 10 distinct haplotypes in 18 families in which we
could follow 22 independent transmission events in which a
heterozygous parent might have transmitted any of the rare
haplotypes to an affected child. We tested our hypothesis by
counting the transmissions from heterozygous parents to affected
offspring, and found a significant transmission bias (p=0.0085,
exact binomial test, one-sided), indicating a positive association
between FMS and rare mutations in the MEFV gene. Rare
MEFV Mutations in Fibromyalgia
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subset of FMS patients with rare alleles had elevated plasma levels
of IL-1b (p=0.019). These findings further support the genetic
and immunological basis of this syndrome.
Results
MEFV Variants in FMS Trios
Based on our previous finding that FMS patients and their
family members had high plasma levels of several cytokines or
chemokines compared to unrelated controls [18], we hypothesized
that the patients had inherited an inflammatory gene. Although a
large number of inflammatory genes have been identified in the
human genome, the MEFV gene family stands out as one of the
founding members of a subgroup containing the PYD domain that
has been linked to the so called inflammasome. We therefore
began our search for a candidate gene in FMS by analyzing the
MEFV gene in one hundred probands with FMS and their parents,
all meeting the ACR criteria for FMS, were recruited into the
study, along with 2 affected siblings. The clinical characteristics of
the patient population were previously published [18]. The MEFV
gene was analyzed in the 100 trios by direct sequencing, a total of
2.63 megabases of genomic sequence. One common and 10 rare
missense variants were identified (Table 1, Figure 1). Seven
probands (FMS45, 127, 254, 316, 495, 501, 549) had one
heterozygous rare mutation; five probands (FMS52, 248, 321, 411,
435) had two rare variants; and three probands and one affected
sibling had three or more rare variants (FMS51, 53, 512, 540).
The family pedigree for FMS53 revealed transmission of two
different rare variant haplotypes for two siblings (Figure S1). In
total, 15 out of 100 probands (and one affected sibling) carried one
or more rare variants (15%) in 10 distinct rare haplotypes. In
addition to these rare missense variants, the common missense
polymorphism, R202Q, was identified in 40 probands (40/
100=40%). The allele frequency of R202Q overall was 23%
(46/200), compared with 29.6% reported in dbSNP controls.
Given that 15% of the probands had one or more rare variants
(Table 1), and our intention was to determine if the rare variants
were inherited in a biased manner, it was clear that the analysis of
multiple subgroups would be underpowered. Based on the fact
that multiple rare MEFV variants were capable of causing FMF if
present on both chromosomes, we decided to test the transmission
of rare variants from parents to offspring collectively.W e
hypothesized that FMS, unlike FMF, would require any of the rare
variants on a single chromosome. Thus the rare variants
collectively would create a risk for FMS but would require a
further event such as an environmental factor to trigger disease.
Table 2 lists the 22 independent events in which a rare allele was
available for transmission from a parent to an affected proband or
sibling. There are multiple lines for some families, with each line
showing which haplotype was transmitted from a heterozygous
parent to an affected child. As stated above, we tested the rare
variants collectively for preferential transmission using the exact
binomial version of the transmission disequilibrium test (TDT), as
described in the Discussion section. In 17 of these 22 events
(independent under the null hypothesis), the rare allele was
transmitted to the affected offspring (p=0.0085). The common
allele R202Q was excluded from the analysis because it is
frequently found in the general population [44] and does not
qualify as rare. As expected, the same analysis for the common
missense change, R202Q, showed no transmission bias to affected
progeny (Table S2). Thus, we obtained evidence that rare alleles,
encoding missense changes for the MEFV gene, were associated
with FMS. The lack of biased transmission of the common allele
from parents to probands suggested that R202Q does not correlate
with risk of FMS and serves as an internal control for transmission
of SNPs within this gene. It should be noted that in transmission
analysis, the parents serve as the ‘‘controls’’ in that transmission of
heterozygous rare alleles from parent to offspring should occur at a
frequency of 0.5 by chance and .0.5 if associated with FMS.
Since we had previously shown that both patients and their
parents had high plasma levels of MCP-1, IP-10 and eotaxin
compared to unrelated controls [18], we decided to re-analyze
these data to test if chemokine and/or cytokine plasma levels were
correlated with the rare MEFV genotypes. As shown in Figure 2,
MCP-1, IP-10 and eotaxin plasma levels were elevated, on
average, for all FMS patients vs. unrelated controls, except those
with the rare alleles for the MEFV gene, who were empirically
intermediate, but cannot be statistically distinguished from either
controls or other FMS patients. However, levels of IL-1b, the chief
Table 1. MEFV mutations identified in the trios.
SNP ID Variants Exon Associated phenotype1 Allele frequency (%) Conservation
FMS dbSNP
2
rs11466018 L110P 2 Unknown 1.5 2.1 chimpanzee, monkey
rs3743930 E148Q 2 FMF atypical; FMF with criteria 3.5 2.1 mouse, rat, chimpanzee, monkey, rabbit, cow
rs224222 R202Q 2 Unknown 22.5 29.6 chimpanzee, rabbit, cow
n/a A289V 2 FMF with criteria 0.5 n/a chimpanzee, monkey
n/a R329H 3 Unknown 0.5 n/a chimpanzee, monkey, rabbit
rs11466023 P369S 3 Unknown 3.5 4.4 mouse, rat, chimpanzee, monkey, rabbit, cow
rs11466024 R408Q 3 Unknown 3.5 2.4 mouse, rat, chimpanzee, monkey, rabbit, cow
n/a A457V 5 Unknown 0.5 n/a chimpanzee, monkey
rs11466045 I591T 9 FMF with criteria 1.1 1.3 chimpanzee, monkey, rabbit
n/a K695R 10 FMF with criteria 0.5 n/a chimpanzee, monkey, rabbit
rs61732874 A744S 10 FMF with criteria 0.5 n/a chimpanzee
1Infevers Database: http://fmf.igh.cnrs.fr/ISSAID/infevers/; a diagnosis of FMF requires compound heterozygotes.
2NCBI SNP database: www.ncbi.nlm.nih.gov/projects/SNP/
doi:10.1371/journal.pone.0008480.t001
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(protein product of the MEFV gene), were high in FMS patients
with the rare MEFV alleles, but not in unrelated controls or FMS
patients with wild type MEFV. Plasma levels of MIP-1a,a
chemokine involved in monocyte migration and activation [45],
were elevated in subjects with the rare MEFV alleles compared to
other FMS patients (p=0.019, legend to Figure 2), who, along
with their relatives, had elevated levels compared to unrelated
controls. MCP-1, a chemokine with similar function, showed no
such distinction of the individuals with rare alleles, but those with
the R202Q polymorphism were strikingly elevated (p=0.004,
legend Figure 2) compared to FMS patients generally, and all
FMS patient and family groups were elevated relative to unrelated
controls. FMS patients and family members without rare variants
differed from control subjects with regard to both TH1 (IFNc) and
TH2 (IL-5 and IL-13) cytokine levels (Figure S2). Those with rare
alleles were similar to other FMS patients and family with regard
to IL-5 levels, but similar to control subjects and distinct from
other FMS patients without rare variants (p=0.003) with regard to
IFNc, and indistinguishable from either group with regard to IL-
Table 2. Transmission of rare variants for FMS trios.
1,2
haplotypes proband mother father allele
ID# genotype ID# genotype ID# genotype ut (C) t (B)
E148Q FMS79 wt FMS80 wt FMS81 het 1 0
FMS203 wt FMS204 wt FMS205 het 1 0
FMS316 het FMS317 het FMS318 wt 0 1
L110P/E148Q FMS52 het FMS54 wt FMS55 het 0 1
FMS53 het FMS54 wt FMS55 het 0 1
FMS248 het FMS247 het FMS249 wt 0 1
R329H FMS45 het FMS47 wt FMS46 het 0 1
P369S/R408Q FMS52 wt FMS54 het FMS55 wt 1 0
FMS53 het FMS54 het FMS55 wt 0 1
FMS321 het FMS322 het FMS323 wt 0 1
FMS340 wt FMS339 wt FMS365 het 1 0
FMS366 wt FMS339 wt FMS365 het 1 0
FMS411 het FMS464 wt FMS463 het 0 1
FMS435 het FMS564 wt FMS508 het 0 1
E148Q/P369S/R408Q FMS51 het FMS49 wt FMS50 het 0 1
FMS512 het FMS511 wt FMS510 het 0 1
E148Q/P369S/R408Q/A457V FMS540 het FMS539 wt FMS538 het 0 1
A289V FMS501 het FMS503 wt FMS502 het 0 1
I591T FMS495 het FMS497 wt FMS496 het 0 1
FMS549 het FMS548 het FMS547 wt 0 1
K695R FMS254 het FMS257 het FMS258 wt 0 1
A744S FMS127 het FMS126 wt FMS130 het 0 1
Total 51 7
1Abbreviations are: wt-wildtype; het: heterozygote.
2Probands FMS52 and FMS53 are sisters that both inherited one set of rare alleles from the father, while one of the sisters inherited rare variants from her mother (see
Supplementary Fig S1.)
doi:10.1371/journal.pone.0008480.t002
Figure 1. Missense mutation detected in the MEFV gene in FMS patients. Part of the genomic organization of the MEFV gene and a map of
the missense mutations in patients with Fibromyalgia Syndrome are illustrated.
doi:10.1371/journal.pone.0008480.g001
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PLoS ONE | www.plosone.org 4 December 2009 | Volume 4 | Issue 12 | e8480Figure 2. Plasma chemokine/cytokine levels by MEFV genotypes in FMS patients and family members, and in unrelated controls. Ctrl:
plasma levels (pg/mL) for unrelated controls (n=77) of unknown genotype. Wt no FMS: unaffected parents without variant alleles (n=35). Wt FMS: FMS
probands (n=37) with wild type (non-variant) MEFV gene. R202Q: FMS probands andfamily members with R202Q genotype (n=49). Rare: FMS patients
with a rare variant of the MEFV gene (n=14). P values are shown below each group. Boxplots indicate the median (heavy bar), central 50% of data (box)
and range of observations (whiskers). P-values are from two-sided t-tests contrasting each group with the control group, using pooled variance, a
logarithmic scale, and without any adjustment for multiple comparisons. In addition, subjects with the rare MEFV alleles compared to wt FMS patients
had elevated levels of MIP-1a (p=0.019); subjects with R202Q polymorphism compared to wt FMS patients had elevated levels of MCP-1 (p=0.004).
doi:10.1371/journal.pone.0008480.g002
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plasma levels for all groups compared to unrelated controls
(Figure 2). In spite of the expected relationship between IL-12
and IFNc [46] in TH1-like diseases, there was no elevation in
IFNc levels (Figure S2), arguing against a TH1 involvement in
FMS.
Discussion
FMF-Related MEFV Variants
Since we have proposed that FMS has an underlying basis in
inflammation [18], we began our search for a candidate gene with
the well-studied MEFV gene associated with FMF. In addition, we
examined NLRP3 (C1AS1 showed a single missense mutation in its
exons) and 3 other genes associated with the inflammasome
(ASC1, ASC2, and CD2BP1 exhibited no missense mutations in
their exons). Since our cohort utilized trios, it was possible to
measure transmission of haplotypes directly from parents to
probands without the need for extensive matching of age,
ethnicity, and other factors that might confound other designs.
Thus, the parents serve as ‘‘controls’’ for the FMS affecteds.
Among the genes analyzed (data not shown) only the MEFV gene
displayed a significant result in terms of rare alleles that were
transmitted from parents to probands. Of interest, these other
genes collectively demonstrated only a few rare missense
mutations.
Our data herein provide strong evidence for the association
between the MEFV structural gene variants and a subset (15%) of
FMS patients. Of the 10 rare missense variants we identified, five
are FMF-related mutations (E148Q, A289V, I591T, K695R,
A744S; INFEVERS Database: http://fmf.igh.cnrs.fr/ISSAID/
infevers/.) E148Q is one of the most common mutations in FMF
patients. It has been proposed that E148Q (together with
another FMF allele) causes a milder disease, although some
reports indicated E148Q should be classified as a polymorphism,
rather than a disease-causing mutation, since it occurs at a
higher frequency in the general population (Table 1). Interest-
ingly, we found three FMS patients carrying three different
mutations, E148Q/P369S/R408Q, which were reported previ-
ously in an FMF patient, all carried in cis on the same allele/
haplotype [47]. No founder mutations (M680V, M694I, M694V
and V726A) of the MEFV gene were identified in our study.
These results support our diagnosis of FMS in this cohort, rather
than variant FMF. Importantly, only a subset of the patient
cohort carry the rare MEFV variants, leaving open the question
of which genes are associated with risk in the remaining 85% of
the patient cohort.
Significance of the Common Mutation, R202Q
R202Q has previously been reported as a common polymor-
phism [44]. There is some evidence suggesting that R202Q
homozygosity increases risk of FMF [48]. Homozygosity of
R202Q has been detected in four of 26 FMF patients and none
of 60 healthy individuals (p=0.007, [49]). The lack of this
homozygous alteration in 60 healthy individuals and nine patients
suffering from other inflammatory diseases raises the possibility of
a cooperative role for R202Q/R202Q in FMF. Although
heterozygous R202Q is common among healthy individuals
[49], its homozygosity in FMF patients may reflect a dosage-
dependent deleterious effect that might require other genetic and
environmental elements for expression. We identified six homo-
zygous R202Q individuals in 100 FMS probands (6%). Analysis of
a larger cohort and functional studies of the R2022Q variant pyrin
protein may assist in understanding the role of this variant in both
FMS and FMF.
Statistical Methodology
Collective testing of haplotypes carrying rare mutations is
motivated by the variety of rare variants that contribute to FMF as
compound heterozgotes and the variety of rare variants acting in a
dominant mode at the cryopyrin gene. The collective testing of
rare alleles at candidate genes is an increasingly common strategy
in genetic epidemiology [50]. Pritchard [51] argues that rare
alleles are, collectively, major contributors to common disorders;
and Kryukov et al [43] assert that rarity of an allele is, by itself, an
indicator of likely deleterious effect. Schork et al. [52] state that
statistical testing of collections of rare variants, as a group, is a new
but ‘‘crucial’’ development in genetic epidemiology.
Because we were interested in testing for dominant genetic
effects (only one affected child was a compound heterozygote) and
because no parents were compound heterozygotes, we were able
to apply a particularly simple test. There were 22 transmission
events in which a heterozygous parent could pass a chromosome
with or without rare variants to their child. If the MEFV variants
were neutral (the null hypothesis), either chromosome would be
equally likely to be transmitted; furthermore, these events are
stochastically independent. If rare variants increase the risk of
FMS, then the fact that affected offspring are sampled will increase
the probability of finding rare variants. We can simply count the
number of transmissions and calculate the significance probability
(p-value) from the binomial distribution, with event probability
0.5, and n=22. This is a test of transmission, but it differs from the
commonly used transmission/disequilibrium test (TDT) in that it
tests rare variants collectively, is one-sided, and only involves only
one mating type. The more commonly employed approximate test
refers (b2c)
2/(b+c) to a chi-square distribution, where b and c are
the respective counts of transmitted and untransmitted candidate
alleles from heterozygous parents; but, as Spielman et al. [53]
noted when proposing this test, ‘‘An exact binomial test can be
used, if desired…’’ Spielman et al. go on to describe an application
to multiple markers in the same manner that we use here; but, as
they were concerned with markers, they imagined collecting alleles
based on prior evidence of association rather than collecting
uncommon missense variants. The major implications of using the
TDT statistic to test a collection of uncommon missense sequences
instead of markers are that (1) the test becomes one-sided (or there
is no basis for collecting multiple variants); (2) the concern about
segregation distortion is greatly reduced; and (3) the various
marker-oriented characterizations of the TDT as a test of linkage
in the presence of association become meaningless, as there is no
marker.
Slager, et al, [54] have shown that the TDT has a dramatic loss
of power when there is allelic heterogeneity. Our one-sample
binomial test handles allelic heterogeneity by simply counting all of
the rare alleles, and maintains the advantages of a family-based
test of linkage and association, essentially using untransmitted
alleles as controls, which provides robustness against spurious
conclusions induced by hidden genetic structure, such as
stratification or admixture. Thus, there is no need to obtain and
study age- and ethnicity-matched controls.
There is a growing discussion among human geneticists that
collections of rare alleles at pathogenetic loci will account for a
significant proportion of genetically-based human disorders [52].
Thus, we feel confident that the analysis presented here is the most
appropriate test for studying the possible association of FMS with
the MEFV gene at this early stage of analysis. Our data suggest
MEFV Mutations in Fibromyalgia
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factor, but only for a subset of FMS patients.
Correlative Studies
The correlation of rare MEFV alleles with elevated chemokine/
cytokine plasma levels is especially intriguing because functional
studies on the pyrin protein would predict disregulation of IL-1b
secretion in patients with chronic inflammation. In our previous
analysis on a subset of patients and parents with FMS, we found
elevation of MCP-1 and eotaxin plasma levels [18], but the
standard deviation on IL-1b levels was large in both controls and
FMS patients, providing no significant difference between the two
groups. However, upon re-analysis of the data comparing FMS
patients with rare MEFV alleles to controls, IL-1b was significantly
elevated (p=0.019). This is the first demonstration of such a
correlation and merits further study in both FMS and FMF
patients. What remains unexplained is the cause of the high MCP-
1 and eotaxin levels in FMS patients, regardless of their genotype.
This suggests that there is an environmental component to the
disease, most likely underlying chronic inflammation, since many
inflammatory stimuli will cause the production of MCP-1, which,
in turn, will activate monocytes. While no evidence of monocytic
infiltrates into skeletal muscle has been found in FMS patients,
there is evidence of skeletal muscle damage [22] that may be
caused by high systemic levels of MCP-1. MCP-1 has been shown
to up-regulate IL-1b expression in monocytes [55]. The specific
interaction of MCP-1 with skeletal muscle has not been studied in
detail, but we have shown that MCP-1 stimulates the release of IL-
1b, IP-10 and eotaxin from myoblasts [18]. In addition, eotaxin is
the natural antagonist for the CCR2 receptor, the main receptor
for MCP-1 [56]. Thus, high levels of eotaxin may reflect an
attempt by skeletal muscle (or other cells) to counteract the effects
of MCP-1. Finally, MCP-1 has a direct effect on sensory neurons,
causing pain [57], and reduces glucose uptake in skeletal muscles
[58], possibly subjecting skeletal muscles to fatigue. What remains
to be explored is the complex connection between the effect of
mutations in inflammation-regulating genes, such as MEFV, and
environmental effects that sustain the production of harmful
chemokines and cytokines, such as MCP-1, eotaxin, and IL-1b.
The lack of the usual wide variation in plasma MCP-1 and IP-
10 levels in FMS patients with the common R202Q allele may
indicate that this variant has a functional connection to the
production of these two cytokines, rather than IL-1b, as seen in the
patients with rare MEFV alleles. It is also noteworthy that patients
with the common polymorphism have depressed levels of IFNc
and IL-13, the former demonstrating a lack of TH1-like disease
(where high IFNc and low IL-13 are expected), and the latter
arguing against TH2-like disease, such as asthma (where high IL-4
and IL-13 are expected). Taken together, these data argue against
aT H1o rT H2 origin for the disease in the 15% of patients with
rare MEFV alleles and the 40% of probands with the common
variant. (In this regard, it is interesting that IL-1b is associated with
innate immunity.) Thus, polymorphisms in the MEFV gene may
predispose up to 55% of probands to an immunological imbalance
in cytokine/chemokine levels.
Finally, we have accounted for a possible disease susceptibility
gene in only a subset of FMS. Given the large number of NLR
genes and their growing number of disease associations, it is likely
that more NLR gene variants will be found as risk factors for FMS,
and that specific chronic infections will be identified that trigger
FMS via their interactions with these genes. Therefore, we are
hopeful that the etiology of FMS will emerge along with its
correlation to genetic risk factors. Importantly, the studies
presented here are correlative and do not provide a mechanistic
explanation for FMS. Studies are now underway to determine if
the rare variants identified confer a phenotype to transfected cell
lines.
Methods
Subjects
The study was approved by the Institutional Review Board of
City of Hope National Medical Center (IRB 04186). Patients with
fibromyalgia recruited into the study contacted their first-degree
relatives, who were subsequently also recruited into the study.
Written informed consent was obtained from all participants in
this study. Probands and affected parents were diagnosed with
FMS fulfilling ACR criteria [3]. Patients with the autoimmune
diseases rheumatoid arthritis (RA) and systemic lupus erythema-
tosus (SLE) were excluded from the study; other clinical
characteristics of the patient population have been previously
described [18]. Unrelated control subjects, as previously described
[18] were used for comparison of cytokine/chemokine levels, but
the genetic analysis used the transmission disequilibrium test,
which avoids the need for unaffected control subjects.
PCR and Sequencing
DNA was isolated from peripheral leukocytes or saliva, using
the QIAamp DNA Blood Mini Kit (Qiagen) and Oragene DNA
Self Collection Kits (DNA Genotek) according to the manufac-
turers’ instructions. All coding exons and splice junctions (except
exon 2) of the MEFV gene were amplified by PCR in a total
volume of 20 ml with 10 mM Tris-HCl, pH 8.3, 50 mM KCl,
1.5 mM MgCl2, 200 mM of each deoxyribonucleoside triphos-
phate, and 0.2 mM of primers. 1 U of Ampli-Taq Gold (Roche)
and 20 ng of genomic DNA were added. Exon 2 was amplified
with the GC-RICH PCR System (Roche). PCR reactions were
performed on the GeneAmp PCR System 9700 (Applied
Biosystems) with denaturation at 94uC for 10 min, and then
denaturation at 94uC for 15 sec, annealing at 60uC for 30 sec, and
elongation at 72uC for 1 min for a total of 35 cycles and a final
elongation for 10 min at 72uC. The amplicons were purified by
ExoSAP-IT and sequenced with the ABI PRISM 3730 (Applied
Biosystems). The sequences of PCR primers are listed in Table
S1. Genomic and amino acid sequences for MEFV were collected
from Ensemble: ENST00000219596, ENSG00000103313.
Statistical Analysis
The statistical considerations are described in detail in the
Discussion section.
Measurement of Cytokines and Chemokines
The plasma level of cytokines and chemokines of a portion of
the cohort described here were previously reported [18]. The
levels were compared in unrelated controls and probands and
family members with wild type MEFV or variant MEFV alleles.
Statistical analysis was performed by a two sided, unpaired
student’s t test.
Supporting Information
Figure S1 Pedigree for family 13 that transmitted multiple rare
alleles to two different offspring. Filled circles are females with
FMS, open square, unaffected father.
Found at: doi:10.1371/journal.pone.0008480.s001 (0.54 MB
TIF)
Figure S2 Cytokines that inversely correlate with rare alleles in
FMS patients and their families. Ctrl: plasma levels (pg/mL) for
MEFV Mutations in Fibromyalgia
PLoS ONE | www.plosone.org 7 December 2009 | Volume 4 | Issue 12 | e8480unrelated controls (n=77), unknown genotype. Wt no FMS:
parents with wild type alleles and no FMS (n=35). Wt FMS: FMS
probands (n=37) with wild type MEFV gene. R202Q: FMS
probands and family members with R202Q genotype (n=49).
Rare: FMS patients with a rare variant of the MEFV gene (n=14).
P values are shown below each group. Boxplots indicate the
median (heavy bar), central 50% of data (box) and range of
observations (wiskers). P-values are from two-sided t-tests con-
trasting each group with the control group, using pooled variance,
a logarithmic scale, and without any adjustment for multiple
comparisons.
Found at: doi:10.1371/journal.pone.0008480.s002 (1.00 MB TIF)
Table S1 Primers for the MEFV gene.
Found at: doi:10.1371/journal.pone.0008480.s003 (0.04 MB
DOC)
Table S2 Genotype of R202Q in trios.
Found at: doi:10.1371/journal.pone.0008480.s004 (0.07 MB
DOC)
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